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ABSTRACT
Introduction: The LEADER trial was a cardio-
vascular (CV) outcomes trial in patients with
type 2 diabetes at high CV risk that compared
liraglutide (n = 4668) with placebo (n = 4672)
using a primary composite endpoint of 3-point
major adverse CV events. The objective of this
post hoc analysis was to investigate glycaemic
outcomes across both treatment groups.
Methods: Glycated haemoglobin (HbA1c) was
measured at randomisation, month 3, month 6
and every 6 months thereafter. Cox regression
was used to analyse time to a composite end-
point of glycaemic deterioration, defined as a
specified change in HbA1c or a substantial
intensification of insulin or oral antihypergly-
caemic drug (OAD). The individual components
of the composite were also analysed.
Results: Baseline characteristics, including
insulin and OAD use, were balanced between
treatment groups. HbA1c decreased from base-
line in both groups, but the reduction was
greater with liraglutide [estimated treatment
difference at month 36: - 0.40%; 95% confi-
dence interval (CI) - 0.45, - 0.34] despite the
addition of more OADs and higher insulin use
in the placebo group. Fewer of the patients
treated with liraglutide (n = 3202, 68.6%)
experienced glycaemic deterioration compared
with those administered the placebo (n = 3988,
85.4%; average hazard ratio: 0.50; 95% CI 0.48,
0.53; p\ 0.001). Analysis of the individual
components showed similar results (both p
\0.001).
Conclusions: Type 2 diabetes patients at high
risk of CV events who were treated with
liraglutide achieved greater reductions in
HbA1c, had a lower risk of hypoglycaemia and
presented less glycaemic deterioration than
similar patients who received the placebo.
Nonetheless, progressive loss of glycaemic con-
trol occurred in both groups.
Trial Registration: ClinicalTrials.gov, NCT011
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PLAIN LANGUAGE SUMMARY
In patients with type 2 diabetes, blood sugar
levels are higher and vary more than in healthy
people. In the past, some drugs that were used
to treat diabetes by controlling blood sugar
levels increased the risk of certain complica-
tions. LEADER was a clinical trial investigating
the impact of a drug called liraglutide on stroke,
heart attack and death in patients with type 2
diabetes. Liraglutide was compared with a pla-
cebo control drug, but all patients were also
allowed to use a range of other diabetes drugs
during the trial if needed to achieve good blood
sugar control. LEADER showed that liraglutide
reduced the risk of the key complications com-
pared with placebo. While LEADER was a safety
study, other variables were also measured. We
examined both the haemoglobin A1C (a mea-
sure of average blood sugar levels) and the need
for additional diabetes drugs as measures of how
well liraglutide controlled blood sugar levels.
We showed that fewer patients treated with
liraglutide experienced a worsening of blood
sugar control or needed additional diabetes
drugs to control blood sugar. This means that
patients treated with liraglutide had better
blood sugar control over time than those who
received the placebo. While blood sugar control
worsened with both placebo and liraglutide
over the 5 years of the study, this worsening was
faster with the placebo.
INTRODUCTION
Glycaemic control is an important factor in the
development of diabetes-related complications
[1–3]. Glucagon-like peptide-1 receptor agonists
(GLP-1RAs) have demonstrated efficacy in gly-
caemic control in patients with type 2 diabetes
[4]; however, for many of these agents, data on
glycaemic control beyond 2 years are lacking.
Prior to the publication of the results from the
Liraglutide Effect and Action in Diabetes: Eval-
uation of Cardiovascular Outcome Results
(LEADER) trial, the same was true for liraglutide,
with few long-duration trials [5, 6]. LEAD-2 [6]
and LEAD-3 [5] demonstrated the efficacy of
liraglutide 1.8 mg over 2 years (mean change
from baseline in glycated haemoglobin [HbA1c]:
- 0.6% and - 1.1%, respectively).
Analysis of the data in the LEADER trial
demonstrated a significant reduction in the
primary endpoint (3-point major adverse car-
diovascular [CV] events [MACE]: the first
occurrence of CV death, nonfatal myocardial
infarction or nonfatal stroke) with liraglutide
versus placebo, both on a background of stan-
dard-of-care treatment [7]. Blood glucose levels
and other laboratory parameters were measured
regularly during the trial [7]. An HbA1c level
of B 7.0% (individualised depending on the
patient) was targeted, modified according to
local guidelines [7]. While Marso et al. analysed
the change in HbA1c levels from baseline to
month 36 of the trial [7], a more detailed anal-
ysis of these data has not yet been published.
The objective of this post hoc analysis of the
LEADER trial is to describe glycaemic effective-
ness and durability with liraglutide compared
with placebo during a follow-up period of up to
5 years in patients with type 2 diabetes at high
CV risk.
METHODS
LEADER (NCT01179048) was a double-blind,
placebo-controlled, event- and time-driven trial
with a follow-up period ranging from 42 to
60 months. Patients were randomly assigned
1:1 to receive liraglutide 1.8 mg (or the maxi-
mum tolerated dose) or placebo once daily,
both in addition to standard-of-care treatment
[7]. Standard-of-care treatment included stress-
ing the importance of all aspects of lifestyle
management for glycaemic control. If HbA1c
remained[7% (or the individualised target)
with trial intervention, investigators were
encouraged to intensify treatment by initiating
or increasing the dose of any
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antihyperglycaemic therapy (except dipeptidyl
peptidase-4 [DPP4] inhibitors, other GLP-1RAs
or pramlintide) [7, 8]. Informed consent was
obtained from all participants in the LEADER
study. All procedures performed in this study
were in accordance with the ethical standards of
the local research committees and with the
1964 Declaration of Helsinki and its later
amendments [7].
The LEADER trial design strived for gly-
caemic equipoise across treatment groups, con-
sistent with CV outcomes trial (CVOT)
protocols for diabetes therapies. This design was
intended to diminish the potential effects of
glycaemic control on CV outcomes. To evaluate
this outcome, HbA1c was measured at ran-
domisation, month 3, month 6 and then every
subsequent 6 months [7]. The changes in HbA1c
over time and at 36 months have been pub-
lished [7] but have not been analysed in detail.
Hypoglycaemia events were captured as
safety endpoints, where severe events were
those requiring assistance from another person,
and confirmed events were those with plasma
glucose levels\3.1 mmol/L [7, 8].
Analysis
A composite endpoint was used to assess gly-
caemic deterioration. It was defined as HbA1c
C 8.0% and reduction in HbA1c\ 0.5% since
the previous visit, or substantial intensification
of insulin or oral antihyperglycaemic drug
(OAD; start of new OAD or start of insulin or
increase of insulin dose C 10 units [U] or addi-
tion of mealtime bolus to basal insulin or a shift
from basal insulin to premixed insulin). The
HbA1c component of this endpoint was
designed to capture:
(a) The non-attainment of an HbA1c target
(B 7.0% or individualised for each patient
at the discretion of the investigator); to
simplify this measure, and based on the
high mean baseline HbA1c value of 8.7%, a
uniform value of 8.0% was selected for this
analysis
(b) Events where therapy no longer reduced
HbA1c (\ 0.5%) in patients with HbA1c
above the target.
With respect to changes in insulin dose, due to
the level of data available, a 10 U increase in
insulin was chosen as a threshold that balances
sensitivity and specificity for deterioration in
glycaemic control.
The Cox regression method was used to
analyse time to glycaemic deterioration in
liraglutide-treated versus placebo-treated
patients. Time to the individual components of
this composite endpoint was also examined
using the Cox regression method.
Cumulative incidence plots were used to
show the time to glycaemic deterioration, and
were estimated using the Aalen–Johansen
method with death as a competing risk factor.
Death was investigated as a competing risk fac-
tor to negate the effect of the treatment imbal-
ance in patients who died before glycaemic
deterioration occurred (greater CV mortality in
the placebo group compared with liraglutide
[7]). The Weibull model was then used to esti-
mate the average event time ratio. The degree of
deviation from proportional hazards was inves-
tigated by fitting the Weibull model by treat-
ment, which allowed the calculation of the
hazard ratio (HR) over time and quartiles of
event time ratios.
Changes from baseline in HbA1c were anal-
ysed by baseline HbA1c quartiles. Upon analys-
ing the baseline HbA1c in all patients, four
quartiles were identified: patients with
HbA1c\7.6%, HbA1c C 7.6% and\8.3%,
HbA1c C 8.3% and\9.4%, and HbA1c C 9.4%,
respectively.
The rate ratios of confirmed and severe
hypoglycaemia events were estimated using a
negative binomial regression using a log link
and the logarithm of the observation time as
offset.
RESULTS
Baseline characteristics were balanced between
the two treatment groups (liraglutide n = 4668;
placebo n = 4672), with a mean age of 64 years,
diabetes duration of 12.8 years and HbA1c of
8.7% [7]. The proportions of patients using
OADs only, insulin only or both were also
similar at baseline in the two treatment groups
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Table 1 Baseline characteristics of the liraglutide and placebo groups, including concomitant antihyperglycaemic treatment
Liraglutide (n = 4668) Placebo (n = 4672)
Male sexa 3011 (64.5) 2992 (64.0)
Age, yearsa 64.2 ± 7.2 64.4 ± 7.2
Diabetes duration, yearsa 12.8 ± 8.0 12.9 ± 8.1
Geographic regiona
Europe 1639 (35.1) 1657 (35.5)
North America 1401 (30.0) 1446 (31.0)
Asia 360 (7.7) 351 (7.5)
Rest of the world 1268 (27.2) 1218 (26.1)
HbA1c, %
a 8.7 ± 1.6 8.7 ± 1.5
BMI, kg/m2 a 32.5 ± 6.3 32.5 ± 6.3
Body weight, kga 91.9 ± 21.2 91.6 ± 20.8
Systolic blood pressure, mm Hga 135.9 ± 17.8 135.9 ± 17.7
Diastolic blood pressure, mm Hga 77.2 ± 10.3 77.0 ± 10.1
Established CVD/chronic kidney disease (age C 50)a,b 3831 (82.1) 3767 (80.6)
CVD risk factors (age C 60)a,c 837 (17.9) 905 (19.4)
Antihyperglycaemic medication at baseline
OAD only 2436 (52.2) 2375 (50.8)
1 OAD 916 (19.6) 894 (19.1)
2 OADs 1357 (29.1) 1321 (28.3)
[2 OADs 163 (3.5) 160 (3.4)
Insulin only 361 (7.7) 377 (8.1)
Insulin ? OAD 1677 (35.9) 1754 (37.5)
Insulin ? metformin 1397 (29.9) 1500 (32.1)
None 194 (4.2) 166 (3.6)
Insulin dose, U





Full analysis set. Data are the mean ± standard deviation or the number of patients (percentage of either liraglutide or
placebo group). Percentage data refer to the proportion of patients
a Data first published in the LEADER primary publication (Marso et al. [7])
b Established CVD was defined as prior myocardial infarction or prior stroke or transient ischaemic attack or prior
revascularisation or[ 50% stenosis of coronary, carotid or lower extremity arteries or documented symptomatic coronary
heart disease or documented asymptomatic cardiac ischaemia or heart failure or chronic kidney disease
c CVD risk factors included microalbuminuria or proteinuria, hypertension and left ventricular hypertrophy, left ven-
tricular systolic or diastolic dysfunction, or ankle-brachial index\ 0.9.
BMI body mass index, CVD cardiovascular disease, HbA1c glycated haemoglobin, OAD oral antihyperglycaemic drug
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(Table 1), and a total of 55% of patients were
insulin naı̈ve. Of patients who were using
insulin at baseline, the mean insulin dose in
both groups was similar in terms of overall dose
and weight-normalised dose (Table 1).
Mean HbA1c decreased from baseline with
both liraglutide and placebo. Previously, we
reported that this reduction was greater with
liraglutide [mean change at month 36: - 1.16%
with liraglutide versus - 0.77% with placebo;
estimated treatment difference at month 36:
- 0.40%; 95% confidence interval (CI) - 0.45,
- 0.34] [7]. This was despite a greater use of
additional glucose-lowering medications in the
placebo treatment group [7]. In our current,
more detailed analysis, we found that of the
patients in the liraglutide group, 41.6% were at
an HbA1c target of\ 7% at month 36, compared
with 25.8% in the placebo group. Analysis of
the change in HbA1c from baseline, according to
baseline HbA1c quartiles, demonstrated that
patients with the highest baseline HbA1c mea-
surement had the largest reductions over the
course of the trial (Fig. S1 in the Electronic
supplementary material, ESM). Differences
between the liraglutide and placebo groups
within these four quartiles were largest during
the first 12–18 months of the trial, after which
the HbA1c levels of both groups converged
(Fig. S1 in the ESM).
This new analysis of the LEADER glycaemic
data demonstrated that the risk of deterioration
in glycaemic control was significantly larger in
patients treated with the placebo (n = 3988,
85.4%) compared with those treated with
liraglutide (n = 3202, 68.6%; average HR of
liraglutide versus placebo: 0.50; 95% CI 0.48,
0.53; p \ 0.001; Table 2, Fig. 1). Fifty percent of
patients in the placebo group experienced gly-
caemic deterioration after only 4.8 months,
compared with after 19.5 months for the
Fig. 1 Cumulative incidence plot of time to HbA1c C 8%
and reduction\ 0.5% since previous visit or substantial
intensification* in insulin or OAD treatment. Aalen–Jo-
hansen plot, with death as a competing risk factor.
*Substantial intensification of insulin or OAD defined as:
start of new OAD; start of insulin; increase in insulin
dose C 10 units; or addition of mealtime bolus insulin to
basal insulin or a shift from basal insulin to premixed
insulin. HbA1c glycated haemoglobin, OAD oral antihy-
perglycaemic drug





Average hazard ratio [95% CI],
p value
Glycaemic deteriorationa 3202 (68.6) 3988 (85.4) 0.50 [0.48; 0.53], p \ 0.001
HbA1c C 8.0% and reduction\ 0.5% 2486 (53.3) 3410 (73.0) 0.50 [0.47; 0.52], p \ 0.001
Substantial intensification of insulin or
OADb
2267 (48.6) 3046 (65.2) 0.59 [0.56; 0.62], p \ 0.001
Cox regression of time to the composite endpoint
a Glycaemic deterioration defined as HbA1c C 8.0% and reduction\ 0.5% since previous visit, or substantial intensifi-
cation of insulin or OAD
b Substantial intensification of insulin or OAD defined as: start of new OAD; start of insulin; increase in insulin dose C 10
U; or addition of mealtime bolus insulin to basal insulin or a shift from basal insulin to premixed insulin.
CI confidence interval, HbA1c glycated haemoglobin, OAD oral antihyperglycaemic drug
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liraglutide group (Fig. 1). The estimated time to
glycaemic deterioration was, on average, three-
fold longer with liraglutide compared with pla-
cebo (Weibull estimate: 3.57; 95% CI 3.28, 3.88;
p \0.0001). The HR estimated from the Wei-
bull model over time for the composite end-
point between the liraglutide and placebo
groups was 0.48 (95% CI 0.46, 0.50) in month 3,
and increased to 0.62 (95% CI 0.58, 0.67) in
month 36. Sensitivity analyses of the composite
by patients who were insulin naı̈ve at baseline
or OAD naı̈ve at baseline did not change the
average HR between liraglutide and placebo
(HR: 0.50; 95% CI 0.47, 0.53; and HR: 0.51; 95%
CI 0.44, 0.58, respectively). The estimated sub-
distribution HR with death as a competing risk
was very similar to the corresponding cause-
specific HR from the Cox regression (data not
shown).
This current detailed analysis of the individ-
ual components of the glycaemic deterioration
composite endpoint demonstrated that both the
HbA1c and the increase in insulin or OAD com-
ponents were significantly different across the
two treatment groups, with more patients in the
placebo group failing to control HbA1c and more
requiring increases in insulin or OAD (Table 2,
Fig. 2). Mean insulin dose increased in both
treatment groups during the trial, and was
higher in the placebo group compared with the
liraglutide group, throughout the trial (Fig. S2 in
the ESM). At month 36, the mean insulin dose
was 49.4 U (n = 2010) in the liraglutide group
and 57.5 U (n = 2506) in the placebo group.
Overall, the risk of patients increasing their
insulin dose by 10 U or more was significantly
higher for those in the placebo group compared
with the liraglutide group (HR 0.61; 95% CI
0.56, 0.65; p \0.001) (Fig. S3 in the ESM).
As previously reported in the primary LEA-
DER publication, analysis of the estimated rate
ratio of severe hypoglycaemic events (liraglu-
tide/placebo) demonstrated that patients trea-
ted with liraglutide had an estimated 31% lower
rate of experiencing such events compared with
the placebo treatment group (treatment rate
ratio: 0.69; 95% CI 0.51, 0.93; p = 0.013) [7]. A
similar trend was apparent for confirmed
hypoglycaemic events (treatment rate ratio:
0.81; 95% CI 0.74, 0.88; p \ 0.001) [7].
DISCUSSION
The analysis described here shows that treat-
ment with liraglutide in the LEADER trial was
associated with lower HbA1c, reduced incidence
of glycaemic deterioration and delayed treat-
ment intensification compared with placebo in
patients with type 2 diabetes at high risk of CV
disease. This was over the trial duration, which
had a median follow-up time of 3.8 years [7],
despite both groups aiming for local standard-
Fig. 2i–ii Cumulative incidence plots for both parts of
the composite endpoint. i Time to HbA1c C 8% and
reduction\ 0.5% since previous visit. ii Time to substan-
tial intensification* of insulin or OAD treatment.
Aalen–Johansen plots, with death as a competing risk
factor. *Substantial intensification of insulin or OAD
defined as: start of new OAD; start of insulin; increase in
insulin dose C 10 units; or addition of mealtime bolus
insulin to basal insulin or a shift from basal insulin to
premixed insulin. HbA1c glycated haemoglobin, OAD oral
antihyperglycaemic drug
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of-care glycaemic targets. Nonetheless, both
treatment groups demonstrated progressive
glycaemic deterioration over the course of the
study, consistent with the progressive nature of
type 2 diabetes.
Long-term, clinical trial data for GLP1-RAs
are relatively scant. Before LEADER, there were
only two trials greater than 1 year in duration,
both of which reported similar HbA1c reduc-
tions from baseline to LEADER [5, 6] (Table S1
in the ESM and [9]). Results from 6 years of
exenatide once-weekly (QW) treatment in the
DURATION-1 trial, uncontrolled, extension
phase (n = 136) reported a decrease in HbA1c of
approximately 1.6% [10]. The generalisability of
this result is limited by the lack of a control
group and the large number of patients who
withdrew consent during the trial, with the
attendant potential for selection bias whereby
those with good responses to study drug likely
continued and those with less benefit may have
preferentially withdrawn [10]. There are also
3-year data for exenatide across three of the
DURATION trials (DURATION-1, -2 and -3), and
pooled data from these trials have demon-
strated that reductions in HbA1c were main-
tained at 1.1% from baseline at year 3 [11].
Similarly, pooled data from five of the HAR-
MONY studies have demonstrated that albiglu-
tide reduced HbA1c by up to 0.92% at the end of
year 3 [12]. Cross-trial efficacy comparisons
should always be made with caution. Such long-
term data provide evidence that the safety and
efficacy of GLP-1RAs reported in the first clinical
trials with a duration of less than 1 year can be
maintained for several years in a large number
of patients.
CVOTs have also been conducted to inves-
tigate other classes of glucose-lowering drugs,
allowing the long-term evaluation of glycaemic
control by sodium-glucose cotransporter 2
inhibitors (SGLT-2is) and DPP-4 inhibitors
[13–18]. They have also reported changes in
glycaemic control, albeit not as their primary
outcome. In EMPA-REG, empagliflozin 25 mg
reduced HbA1c from baseline by 0.36% at week
206 (* 4 years) compared with placebo [13],
while in CANVAS, canagliflozin reduced it by
0.58% at week 338 (* 6.5 years) [14]. For DPP4
inhibitors, sitagliptin decreased HbA1c by 0.29%
in TECOS versus placebo [15], alogliptin by
0.33% in EXAMINE [18], and saxagliptin by
0.2% in SAVOR-TIMI 53 [16, 17]. Liraglutide
(difference versus placebo of - 0.4%; [7]) com-
pared favourably with these other classes of
glucose-lowering drugs.
Although the degree of reduction in HbA1c
from baseline observed in the LEADER trial
(approximately 1%) demonstrates the effec-
tiveness of liraglutide in patients with advanced
type 2 diabetes, the trial did reveal significant
glycaemic deterioration over 5 years. This is
expected with the progressive nature of type 2
diabetes and has been seen in a similar trial [17],
and it occurred more frequently in the placebo
than in the liraglutide group. At the end of the
LEADER trial, the vital status of 99.7% of
patients was known, with a total of 96.8%
attending a final visit, dying or experiencing a
primary outcome [7]. This high retention rate
provides confidence in our results and is some-
what greater than retention rates in other trials
(46–66%), though these rates may not be
directly comparable [10–12].
Though the general target for HbA1c in the
LEADER protocol was B 7% [7, 8]; it was meant
to be individualised, based on investigator dis-
cretion [8]. A change of 0.5% HbA1c is the
generally accepted minimal clinically impor-
tant difference [19, 20]. Therefore, the com-
posite endpoint in this analysis used an HbA1c
cutoff of C 8.0% and/or a reduction in
HbA1c\0.5% between visits (every 6 months
for most of the trial) as a composite index of
glycaemic deterioration.
It is not surprising that the glycaemic effec-
tiveness observed with liraglutide was achieved
with fewer additions of glucose-lowering medi-
cations [7] and a lower insulin dose compared
with the placebo group. Of particular interest,
this was also associated with a reduction in
severe hypoglycaemia. The LEADER trial had
specific standard-of-care guidelines in which
investigators were able to treat hyperglycaemia
with few restrictions, except that it was recom-
mended that the daily dose of premixed insulin
was not increased during the first 2 weeks post-
randomisation, and if HbA1c was\8%, it was
recommended that the daily dose was decreased
by 20% [7, 8]. This contrasts with other CVOTs,
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such as EMPA-REG OUTCOME, where the
baseline antihyperglycaemic medication had to
remain unchanged for the first 12 weeks of trial
participation [13]. The LEADER protocol did not
allow the use of other GLP-1RAs or DPP-4
inhibitors, as these two classes overlap in
mechanistic pathways with liraglutide, poten-
tially confounding the CV outcome results of
the trial. SGLT-2is were not available at the time
of LEADER trial initiation, their CV risk profile
was unknown when the study was conducted,
and the safety of their combination with GLP-
1RAs had not been established. As a result,
investigators were discouraged from adding
SGLT-2is later, and less than 3% of patients in
both treatment groups were prescribed SGLT-2is
during the trial [7].
There are limitations to these analyses. They
are post hoc. The results may be affected by the
use of a wide range of concomitant medications
and the masking of liraglutide and placebo, but
this was otherwise a relatively real-world setting
reflecting how liraglutide might be used in
clinical practice. The limitations of the original
trial also apply, in that it was completed within
a pre-specified population (i.e. patients with
type 2 diabetes and at high risk for CV events)
[7].
CONCLUSION
In conclusion, in the LEADER trial, patients
with advanced type 2 diabetes at high CV risk
treated with liraglutide experienced greater
reductions in HbA1c and a lower risk of gly-
caemic deterioration and hypoglycaemia when
compared with patients treated with placebo,
despite the increased use of other glucose-low-
ering medications and higher insulin doses in
the placebo group. Nevertheless, both treat-
ment groups experienced a progressive loss of
glycaemic control.
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